Menu
Search
|

Menu

Close
X

Aduro Biotech Inc ADRO.OQ (NASDAQ Stock Exchange Global Select Market)

7.05 USD
+0.25 (+3.68%)
As of Jul 19
chart
Previous Close 6.80
Open 6.75
Volume 90,217
3m Avg Volume 124,724
Today’s High 7.20
Today’s Low 6.75
52 Week High 14.00
52 Week Low 5.85
Shares Outstanding (mil) 78.73
Market Capitalization (mil) 539.30
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
7
FY17
17
FY16
51
FY15
73
EPS (USD)
FY18
-0.276
FY17
-1.214
FY16
-1.397
FY15
-0.708
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.86
Price to Sales (TTM)
vs sector
26.84
8.16
Price to Book (MRQ)
vs sector
2.71
4.20
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
0.00
17.38
LT Debt to Equity (MRQ)
vs sector
0.00
13.24
Return on Investment (TTM)
vs sector
-22.23
13.13
Return on Equity (TTM)
vs sector
-41.39
15.07

EXECUTIVE LEADERSHIP

Stephen Isaacs
Chairman of the Board, President and Chief Executive Officer, Since 2008
Salary: $572,000.00
Bonus: --
Jennifer Lew
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Blaine Templeman
Executive Vice President, General Counsel, Secretary, Since 2015
Salary: $459,000.00
Bonus: --
Dirk Brockstedt
Executive Vice President of Research and Development, Since 2016
Salary: --
Bonus: --
Andrea van Elsas
Chief Scientific Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

740 Heinz Ave
BERKELEY   CA   94710-2748

Phone: +1510.8484400

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.

SPONSORED STORIES